Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy
Launched by BAXTER HEALTHCARE CORPORATION · Oct 20, 2009
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female subject is 18 to 75 years of age at the time of screening
- • Subject is planned for facial rhytidectomy
- • Subject has read, understood and signed the written informed consent
- • Subject is healthy, as determined by the investigator using standard pre-operative assessments to include laboratory tests and electrocardiograms
- • Subject is of childbearing potential, presents with a negative serum pregnancy test, and agrees to employ adequate birth control measures for the duration of the study
- • Subject is willing and able to comply with the requirements of the protocol
- Exclusion Criteria:
- • Subject is indicated for an abbreviated or modified face-lift procedure such as deep plane procedures, minimal undermining procedures, thread lifts, and minimal access cranial suspension
- • Subject is indicated for concurrent facial surgeries during the operation (eg forehead plasty,blepharoplasty, rhinoplasty, buccal fat removal, any filler injections including fat injections, lip augmentation, skin resurfacing procedures etc.)
- • Subject is indicated for additional procedures to the body during the same operation (eg liposuction, mastoplasty etc.)
- • Subject has undergone a prior rhytidectomy surgery
- • Subject is an active smoker, as assessed by the investigator
- • Subject has a known (documented) bleeding or coagulation disorder
- • Subject is being treated with anti-coagulants or with Aspirin (that was not discontinued 7 days prior to surgery)
- • Subject has a vascular disorder, cardiovascular disease, and/or uncontrolled hypertension
- • Subject has diabetes mellitus with glycosylated hemoglobin (HbA1c) \> 7
- • Subject is receiving active treatment for a malignancy
- • Subject has a connective tissue disorder
- • Subject has an active or chronic skin disorder
- • Subject has history of Bell's palsy
- • Subject has a documented history of pathologically or pharmacologically induced immune deficiency
- • Subject has received chronic treatment with immunosuppressive drugs, systemic corticosteroids, or other chronic treatments within 30 days prior to the surgery
- • Subject has a known sensitivity to components of FS VH S/D 4 s-apr
- • Subject has a known psychiatric disorder (eg, obsessive compulsive disorder, anxiety, eating disorders, etc.)
- • Subject has documented healing complications following previous surgeries (eg, hypertrophic scarring)
- • Subject is pregnant or lactating at the time of enrollment
- • Subject has participated in another clinical study involving an investigational product/device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product/device during the course of this study
About Baxter Healthcare Corporation
Baxter Healthcare Corporation is a global leader in the healthcare industry, dedicated to advancing medical innovation and improving patient outcomes through its comprehensive portfolio of products and services. With a strong focus on areas such as renal care, surgical solutions, and hospital products, Baxter leverages cutting-edge research and development to address the evolving needs of patients and healthcare providers. The company is committed to conducting high-quality clinical trials that adhere to rigorous ethical standards, ensuring the safety and efficacy of its therapies while fostering collaboration with healthcare professionals and regulatory bodies worldwide. Baxter's mission is to enhance the quality of life for patients through innovative and reliable healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Dallas, Texas, United States
Chattanooga, Tennessee, United States
Beverly Hills, California, United States
Evans, Georgia, United States
Hewlett, New York, United States
Patients applied
Trial Officials
Steve Z Abrams, MD
Study Director
Baxter Healthcare Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials